OpGen, a precision medicine manufacturer to merge business with Curetis, a developer of molecular diagnostic solutions. Financial terms were not disclosed. "We are convinced that the combination of OpGen and Curetis will help maximize value for our stockholders and will result in an organization with a robust pipeline of molecular diagnostic and bioinformatics products, significant management experience, and proprietary assets for developing and commercializing novel data-driven solutions in infectious disease diagnostics,” Evan Jones, OpGen Chairman and CEO. Curetis shareholders have voted to approve the merger.